مباشر

FierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation CellReplaying germinal center evolution on a quantified affinity landscape CellXenophagocytosis blockade enhances interspecies chimerism FierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy Endpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetes Endpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year Endpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and more FierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs Brady CorporationLabel Maker Market Forecast Points Higher Toward 2035, Driven by Commercial Micro-Enterprise Demand - IndexBox

FierceBiotech ٥ فبراير ٢٠٢٦

Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024

Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024

المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.